Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/24—Heavy metals; Compounds thereof
  • A61K33/243—Platinum; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention relates to combinations of taxol, Taxotere and their
• Taxol Taxol, Taxotere and their analogues, which possess noteworthy antitumor
• subject to be treated are between 1 and 10 mg/kg administered intraperitoneally
• agents such as cyclophosphamide, isosfamide, melphalan, hexametyl-
• melamine thiotepa or dacarbazine
• antimetabolites such as pyrimidine
• analogues for instance 5-fluarouracil and cytarabine, or its analogues such as 2-
• flourodeoxycytidine or folic acid analogues such as methotrexate, idatrexate or
• spindle poisons including vinca alkaloids such as vinblastine or
• vincristine or their synthetic analogues such as navelbine, or estramustine or
• taxoids such as etoposide or teniposide
• epidophylloptoxins such as etoposide or teniposide
• antibiotics such as
• daunorubicine doxorubicin
• bleomycin bleomycin or mitomycin
• enzymes such as L-
• topoisomerase inhibitors such as camptothecin derivatives
• growth factor inhibitors such as interferons or interleukins.
• haematopoietic type such as G-CSF or GM-CSF or certain interleukins with
• Taxol Taxotere, their analogues or their combinations with other therapeutically
• the invention relates to combinations of taxol, Taxotere
• doxorubicin doxorubicin
• cisplatin navelbine
• camptothecin camptothecin
• etoposide doxorubicin, cisplatin, navelbine, camptothecin, and etoposide.
• This efficacy may be quantified, for example, by the log 10 cells killed, which is
• T - C represents the time taken for the cells to grow, which is the mean
• the efficacy of the combinations on solid tumors may be determined
• mice The animals subjected to the experiment, generally mice.
• tumors are mixed before being subjected to the various treatments and controls.
• tumors are treated before being subjected to the various treatments and controls.
• tumors are treated before being subjected to the various treatments and controls.
• the selected animals are distributed at
• Chemotherapy generally begins from 3 to 22 days after grafting,
• the tumors are measured 2 or 3 times a week until the tumor reaches
• the antitumor activity is determined in accordance with the different conditions
• the antitumour activity is determined by the
• chemotherapeutic agents such as cyclophosphamide (alkylating agent), 5-
• fluorouracil antimetabolite
• etoposide semisynthetic podophyllotoxin agent
• vincristine vinca alkaloid
• debenzoyl-N-t-butoxy-carbonyl-7-deoxy-8-desmethyl-7, 8-cyclopropataxotere (hereinafter acetocyclopropyl taxotere) with several chemotherapeutic agents.
• agents such as doxorubicin (antibiotic), cisplatin (platinum coordination
• mice bearing s.c. transplantable tumors were evaluated in mice bearing s.c. transplantable tumors.
• the tumor model
• CTI CTI index
• the CTI represents the sum of the fractions of the lethal dose 10% (LD 10 )
• a CTI of 1 indicates that only 50% of the LD 10
• each single agent (or any of the ratios, 70:30, 40:60, etc ). can be used in
• acetocyclopropyl taxotere had a log cell kill of 2.9 and doxorubicin-3.0.
• HNTD of each single agent can be combined without additional toxicity.
• mice were not
• CPT-11 CPT-11 .
• CTI of 0.6 indicates an important overlap in host toxicity.
• doxorubicin or navelbine were well tolerated with a CTI of approximately 1.4,
• the present invention also relates, therefore, to pharmaceutical compositions containing the combinations according to the invention.
• the constituents of which the combination are composed may be any constituents of which the combination are composed.
• compositions according to the invention are preferably compositions
• compositions which can be administered parentally.
• these compositions may be any compositions which can be administered parentally.
• these compositions may be any compositions which can be administered parentally.
• these compositions may be any compositions which can be administered parentally.
• compositions for parental administration are generally
• non-aqueous solutions or suspensions natural vegetable oils such as olive oil,
• sesame oil or liquid petroleum or injectable organic esters such as ethyl oleate
• the sterile aqueous solutions can consist of a solution of the
• aqueous solutions are suitable for intravenous
• isotonic for example with a sufficient amount of sodium chloride or glucose.
• sterilization may be carried out by heating or by any other means which does not
• the combinations may also take the form of
• liposomes or the form of an association with carriers as cyclodextrins or
• compositions for oral or intraperitoneal administration are preferably
• the combinations according to the invention are especially useful in the treatment of cancers of the colon, breast, ovary or lung, as well as melanoma

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Inorganic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Plant Substances (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=25211230

Family Applications (2)

Family Applications After (1)

Country Status (19)

Cited By (3)

Families Citing this family (21)

Family Cites Families (14)

• 2001
  • 2001-03-21 US US09/813,018 patent/US6441026B1/en not_active Expired - Fee Related
• 2002
  • 2002-03-21 WO PCT/IB2002/002239 patent/WO2002074232A2/en not_active Ceased
  • 2002-03-21 EP EP02713093A patent/EP1478355B1/en not_active Expired - Lifetime
  • 2002-03-21 AT AT02713093T patent/ATE355837T1/de active
  • 2002-03-21 HU HU0500478A patent/HUP0500478A2/hu unknown
  • 2002-03-21 WO PCT/IB2002/000853 patent/WO2002074289A2/en not_active Ceased
  • 2002-03-21 JP JP2002572997A patent/JP4467885B2/ja not_active Expired - Lifetime
  • 2002-03-21 MX MXPA03008539A patent/MXPA03008539A/es active IP Right Grant
  • 2002-03-21 CN CNA028068572A patent/CN1536995A/zh active Pending
  • 2002-03-21 CN CNA2009101299448A patent/CN101590057A/zh active Pending
  • 2002-03-21 DK DK02713093T patent/DK1478355T3/da active
  • 2002-03-21 CA CA2440160A patent/CA2440160C/en not_active Expired - Lifetime
  • 2002-03-21 DE DE60218751T patent/DE60218751T2/de not_active Expired - Lifetime
  • 2002-03-21 EA EA200301047A patent/EA006878B1/ru not_active IP Right Cessation
  • 2002-03-21 ES ES02713093T patent/ES2282400T3/es not_active Expired - Lifetime
  • 2002-03-21 SI SI200230525T patent/SI1478355T1/sl unknown
  • 2002-03-21 PT PT02713093T patent/PT1478355E/pt unknown
  • 2002-03-21 BR BR0208274-8A patent/BR0208274A/pt not_active IP Right Cessation
  • 2002-03-21 AU AU2002244877A patent/AU2002244877B2/en not_active Ceased
• 2003
  • 2003-09-18 IL IL157992A patent/IL157992A/en not_active IP Right Cessation
• 2007
  • 2007-05-10 CY CY20071100643T patent/CY1106582T1/el unknown

Also Published As

Similar Documents

Legal Events